412278-02-5

Basic information

• Product Name: tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate
• Synonyms: tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate
• CAS NO: 412278-02-5
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26276
• Mol File: 412278-02-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 277.2±33.0 °C(Predicted)
• Appearance: /
• Density: 1.103±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.80±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate(412278-02-5)
• EPA Substance Registry System: tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate(412278-02-5)

Safety Data

• Hazardous Substances Data: 412278-02-5(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 3-hydroxy-3-Methylpyrrolidine-1-carboxylate is a chemical compound with the molecular formula C10H19NO3, indicating that it comprises carbon, hydrogen, nitrogen and oxygen atoms. Its precise molecular structure consists of a pyrrolidine ring, which is a five-membered ring with one nitrogen atom, substituted with a tert-butyl ester and a 3-hydroxy-3-methyl group. Commonly used in various scientific and chemical research, this substance is typically a synthetic intermediate in the manufacture of more complex compounds. It is a colourless or slightly yellow liquid at room temperature, with specific physical and chemical properties, such as boiling point, melting point, and flash point, that may vary based on purity and specific methods and conditions of synthesis and storage.

Upstream product

• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 
• 917-64-6 methyl magnesium iodide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1404062-91-4 (4S)-3-[1-(3,3-diphenylpropyl)-3-methylpyrrolidin-3-yl]5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404063-65-5 (R)-1-(3,3-diphenylpropyl)-3-methylpyrrolidin-3-ol 
• 1404062-97-0 (4S)-3-[3-methyl-1-(3-phenylpropyl)pyrrolidinyl-3-yl]-5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404063-68-8 3-methyl-1-phenylethylpyrrolidin-3-ol 
• 1404062-98-1 (4S)-3-(3-methyl-1-phenylethylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404062-99-2 (4S)-3-[1-(3,5-difluorobenzyl)-3-methyl-3-pyrrolidin-3-yl]5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404062-95-8 (S)-3-[(R)-1-(2,2-diphenylethyl)-3-methylpyrrolidin-3-yl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404062-96-9 (S)-3-[(S)-1-(2,2-diphenylethyl)-3-methylpyrrolidin-3-yl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1404063-62-2 1-(3-hydroxy-3-methylpyrrolidin-1-yl)-3,3-diphenylpropyl-1-one 

Relevant articles and documents

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Oxalates as Activating Groups for Alcohols in Visible Light Photoredox Catalysis: Formation of Quaternary Centers by Redox-Neutral Fragment Coupling

Alkyl oxalates are new bench-stable alcohol-activating groups for radical generation under visible light photoredox conditions. Using these precursors, the first net redox-neutral coupling of tertiary and secondary alcohols with electron-deficient alkenes is achieved.

1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof

The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R1, R2, R3, R4, R5, R6, R7, R8, m, n1, n2, p and q are the same as those defined in the description.